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Abstract 20 
The aim of this study was to compare and correlate antibody titres against porcine circovirus 21 
type 2 (PCV2) in porcine sera (n = 1270) obtained by immunoperoxidase monolayer assay (IPMA) 22 
with the results of three commercial ELISAs (designated E1, E2 and E3). The correlation between 23 
IPMA and ELISA results was excellent (r
2
 ≥ 0.90). Compared to IPMA, E2 had the highest 24 
sensitivity (93.0%), followed by E3 (90.1%) and E1 (85.0%); the specificity was 100% for all tests. 25 
All three commercial ELISAs had predictive values similar to those of IPMA and could be used to 26 
monitor antibody responses against PCV2 infection and/or vaccination. 27 
 28 
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The immunoperoxidase monolayer assay (IPMA) is used widely for detection of antibodies 30 
against porcine circovirus type 2 (PCV2) (Opriessing et al., 2007; Fort et al., 2009; Fraile et al., 31 
2012a and b). Neutralising antibodies (NAs) are the main antibodies responsible for protection and 32 
clearance of PCV2 infection (Meerts et al., 2005; Fort et al., 2007). Since there is a positive 33 
correlation between IPMA titres and titres of NAs (Fort et al., 2008, 2009), IPMA titres might be 34 
considered to be an indirect measure of NAs. Furthermore, high levels of maternally derived 35 
antibodies (IPMA titres ≥ 10 log2) appear to interfere with the development of humoral immunity 36 
after vaccination, while IPMA levels < 8 log2 do not have this effect (Fort et al., 2009; Fraile et al., 37 
2012a, 2012b). 38 
 39 
IPMA is relatively complex technique for routine diagnostic use, since it depends on the 40 
availability of virus infected cell cultures, requires a high level of technical expertise and is 41 
relatively slow for screening large numbers of sera. For these reasons, replacement of IPMA by 42 
automated serological tests with an objective end-point reading system, such as ELISAs, is 43 
desirable. The aim of this study was to compare and correlate the antibody titres determined by 44 
IPMA with the results of three commercial ELISAs and to determine if ELISA results can be useful 45 
to infer IPMA titres. 46 
 47 
Sera used in this study (n = 1248) came from a previous study performed on a commercial 48 
farm with a previous diagnosis of PCV2 systemic disease (formerly known as postweaning 49 
multisystemic wasting syndrome) (Fraile et al., 2012b). One week before mating, 57 sows were 50 
randomly divided into two groups: (1) vaccinated sows (V; n = 26) receiving an intramuscular dose 51 
of Porcilis PCV (Intervet International BV) and unvaccinated sows (not vaccinated, NV, n = 31) 52 
receiving phosphate buffered saline (PBS) as placebo. At 4 weeks of age, 208 healthy piglets from 53 
these sows were divided into two groups; 106 piglets were vaccinated with Porcilis PCV and 102 54 
piglets received only PBS. The following groups were included in the analysis: (1) NV piglets from 55 
NV sows (NV-NV, n = 50); (2) V piglets from NV sows (NV-V, n = 52); (3) NV piglets from V 56 
sows (V-NV, n = 52); and (4) V piglets from V sows (V-V, n = 54). Blood samples were collected 57 
from piglets at 4, 12, 16, 21 and 26 weeks of age. In addition, 22 sera from 7- to 10-day-old 58 
Caesarean-derived, colostrum-deprived (CDCD) piglets were included in the study as negative 59 
controls. Animal care and study procedures were conducted in accordance with the guidelines of 60 
Good Experimental Practice, under the approval of the Ethical and Animal Welfare Committee of 61 
the Universitat Autònoma of Barcelona (Reference 665M2; approval on October 24
th
, 2013). 62 
 63 
To detect anti-PCV2 antibodies, all serum samples (n = 1270) were analysed by IPMA and 64 
three commercial ELISAs: (1) SerELISA PCV2 Ab Mono Blocking (Synbiotics; E1); (2) Ingezim 65 
Circo IgG 11. PCV.K1 (Ingenasa; E2); and (3) PCV2 ELISA SK105 (Biochek; E3). Serum samples 66 
were analysed by IPMA in four-fold dilutions from 1:20 to 1:20,480 (Rodríguez-Arrioja et al., 67 
2000). Results were expressed as log2 of the inverse of titre values. All samples with ≥ 4.32 log2 68 
titre were considered to be positive. ELISAs were performed following the manufacturers’ 69 
instructions and sera were analysed at 1:1000, 1:200 and 1:50 dilutions by E1, E2 and E3, 70 
respectively. 71 
 72 
ELISA values were expressed as antibody titres according to the mathematical formula 73 
provided by each manufacturer and the corresponding plate-specific cut-off values were applied to 74 
convert the ELISA results into categorical data. Results for E1 (blocking ELISA) were converted to 75 
reciprocal optical density (OD) values (RecOD, calculated by subtracting the inverse of the OD of 76 
negative control samples to the inverse of the OD of the test sample). Results for E2 and E3 77 
(indirect ELISAs) were expressed as S/P values (S = sample optical density, OD; P = mean positive 78 
control OD). 79 
 80 
Average ELISA RecOD, S/P values and titres corresponding to each IPMA result, as well as 81 
Pearson (r) and determination (R
2
) coefficients between serological values, were calculated for the 82 
three ELISA tests. The equation line (y = ax + b) and curve (y = ax
2
 + bx + c) that best represented 83 
the relationships between IPMA and ELISA values was adjusted to allow the IPMA titre to be 84 
inferred from any ELISA result. 85 
 86 
To ascertain if commercial ELISAs are reliable potential substitutes of IPMA, the sensitivity 87 
(Se) and specificity (Sp) of each ELISA kit was calculated using IPMA qualitative results as 88 
indicators of the true positive status of samples. The overall percentage of agreement (number of 89 
positive plus negative coincident results divided by the number of estimations), along with the 90 
Kappa coefficients (κ values), among serological assays were calculated for paired tests. The 91 
average values of antibody titres, RecOD and S/P ratios for each treatment group at different 92 
sampling times were used to generate antibody profiles. Antibody profiles of different groups for 93 
each serological technique were compared with the Mann-Whitney U test. 94 
 95 
Table 1 summarises IPMA results and corresponding average values for ELISA RecOD, S/P 96 
values and titres. As indicated by the R
2
 value, the correlation between IPMA and E1 results was > 97 
0.92 for RecOD and ELISA values when both linear and polynomial equations were considered 98 
(Fig. 1). Considering a linear relationship between IPMA and E2 results, the correlation was low for 99 
ELISA titres (R
2
 = 0.48) and relatively high for S/P ratio values (R
2
 = 0.7) (Fig. 1). Nevertheless, R
2
 100 
increased to 0.91 and 0.97 for E2 titres and S/P ratios, respectively, when a polynomial equation 101 
was considered (Fig. 1). The coefficient of correlation was > 0.88 for both S/P and E3 titres when a 102 
linear equation was considered (Fig. 1). R
2
 increased to 0.90 for both S/P values and E3 titres when 103 
the polynomial equation was used (Fig. 1). 104 
 105 
All serum samples were PCV2 IPMA positive; CDCD pig sera resulted negative. E2 had the 106 
highest Se (93.02%), followed by E3 (90.14%) and E1 (85.02%). Serum samples from CDCD pigs 107 
were negative in all three ELISAs; thus Sp was 100% for all ELISAs. The overall percentage of 108 
agreement and κ coefficients among ELISAs are shown in Table 2. More significant differences in 109 
antibody profiles among treatment groups were evident using E2 than IPMA, E1 or E3 (Fig. 2). 110 
 111 
All ELISAs had good diagnostic accuracy and could be used to discriminate and interprete 112 
the antibody profiles obtained at farm level, although the agreement between ELISAs was fair to 113 
moderate. On the basis of the determination coefficient, the correlations between IPMA and the 114 
three ELISAs were excellent (R
2
 ≥ 0.90). It was possible to infer an IPMA titre from each RecOD 115 
or S/P value, and vice versa, by means of linear or polynomial equations. The equivalence between 116 
IPMA and ELISA results should be useful for monitoring antibody titres due to PCV2 infection and 117 
vaccination. According to observations by Fort et al. (2009) and Fraile et al. (2012a and 2012b), 118 
maternally derived IPMA titres ≥ 10 log2 interfere with seroconversion following PCV2 119 
vaccination. The present study shows that ELISA values can be used to infer IPMA titres in order to 120 
select the age at vaccination that prevents this interference.  121 
 122 
All tests used in the present study (IPMA, E1, E2 and E3) were able to detect the presence 123 
of maternally derived antibodies at 4 weeks of age based on antibody profiles. At this sampling 124 
time, piglet groups from vaccinated sows had the highest calculated antibody titres in all ELISAs 125 
and by IPMA. Passive antibodies waned and reached their minimum level between 8 and 12 weeks 126 
of age, depending on the treatment received by the sow and the antibody values at weaning. The 127 
three ELISA tests, as well as the IPMA technique, also detected seroconversion by 21 weeks of age. 128 
In contrast to the other serological assays used in this study, E3 was not able to detect overt 129 
seroconversion due to piglet vaccination at 8 weeks of age. 130 
 131 
E2 was the most suitable kit to detect significant differences between treatment groups, 132 
followed by IPMA, E1 and E3. The differential ability to detect seroconversion due to piglet 133 
vaccination and to discriminate between vaccine treatment groups could be a consequence of the 134 
different types of antibodies detected by each assay. The types of antibodies detected by E1 and E3 135 
are not clear. Considering the intrinsic characteristics of a blocking ELISA, we speculate that total 136 
antibodies were detected by E1, whereas E2 only detects IgG, as indicated by its manufacturer. In 137 
the case of IPMA, a peroxidase-conjugated protein A was used to develop the reaction, also 138 
specifically detecting porcine IgG antibodies. This should be kept in mind when comparing and 139 
interpreting test results within and between laboratories (Patterson et al., 2011). 140 
 141 
In conclusion, the results of the present study indicate that all three commercial ELISA 142 
assays provided predictive values similar to those offered by IPMA and represent reliable potential 143 
substitutes for IPMA to monitor antibody responses against PCV2 infection and/or vaccination in 144 
quantitative and qualitative terms. 145 
 146 
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Table 1 199 
Average RecOD, S/P ratio values and calculated ELISA titres for each immunoperoxidase monolayer assay (IPMA) 200 
titre and the corresponding 95% confidence intervals. 201 
 202 
IPMA 
titre 
Number of 
samples 
E1 E2 E3 
RecOD Titre S/P Titre S/P Titre 
4.32 9 0.15 [-0.06;0.35] 318 [138;498] 0.98 [0.48;1.48] 12117 [-3887;28122] 0.97 [0.50;1.44] 2279 [1101;3457] 
6.32 73 0.16 [0.10;0.22] 432 [334;529] 0.59 [0.51;0.68] 1440 [83;2795] 0.85 [0.73;0.97] 1972 [1679;2266] 
8.32 213 0.35 [0.28;0.41] 618 [537;700] 0.83 [0.77;0.89] 3552 [1835;5269] 1.03 [0.95;1.11] 2420 [2214;2625] 
10.32 310 0.66 [0.60;0.72] 987 [903;1072] 1.11 [1.06;1.16] 4869 [3919;5819] 1.35 [1.28;1.41] 3223 [3051;3396] 
12.32 297 0.89 [0.83;0.96] 1322 [1226;1418] 1.38 [1.33;1.43] 16610 [10364;22857] 1.53 [1.46;1.59] 3692 [3524;3859] 
14.32 345 0.87 [0.81;0.92] 1545 [1453;1636] 1.68 [1.63;1.74] 45004 [27385;62623] 1.63 [1.55;1.67] 3908 [3752;4064] 
 203 
Lower and upper limits of the confidence intervals are shown between brackets. 204 
Table 2 205 
Overall percentage of agreement and κ coefficients between ELISAs. 206 
 207 
 
E2 
 
E3 
E1 Positive Negative Total  Agreement κ* Kmax**   Positive Negative Total  Agreement κ* Kmax** 
Positive 1024 37 1061 
    
995 66 1061 
   
Negative 137 72 209 
    
130 79 209 
   
Total 1161 109 1270 86.3% 0.383 [0.311;0.455] 0.731 
 
1125 145 1270 84.6% 0.360 [0.289;0.430] 0.698 
E2 
             
Positive 
       
1086 75 1161 
   
Negative 
       
39 70 109 
   
Total 
       
1125 145 1270 91.0% 0.502 [0.423;0.581] 0.821 
 208 
*Lower and upper limits of the confidence intervals of κ coefficient are shown between brackets. 209 
**The maximum obtainable Kappa (Kmax) reflects how much an imbalanced positive and negative classification constrains the agreement between 210 
techniques, being the prevalence of the  classifications one of the factors that could reduce the K value.   211 
Figure legends 212 
 213 
Fig. 1. (A) Correlation (R
2
) between average immunoperoxidase monolayer assay (IPMA) titres and 214 
average ELISA RecOD or S/P values of commercial porcine circovirus type 2 ELISA kits E1, E2 215 
and E3, respectively. (B) Correlation (R
2
) between average IPMA and ELISA titres. Linear (y = ax 216 
+ b) and polynomial (y = ax
2
+ bx + c) equations defined the lines (continuous) and curves (dashed), 217 
respectively, that best represented the relationship between IPMA and ELISA values for each 218 
serological technique. 219 
 220 
Fig. 2. Antibody profiles of the different treatment groups obtained by immunoperoxidase 221 
monolayer assay (IPMA) and ELISAs E1, E2 and E3 (panels A, B, C and D, respectively). Mean 222 
and standard error (indicated by error bars) of serological values for each group and sampling time 223 
is represented in each figure. 224 
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